- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Dr. Reddy's in the news
-
No Indian pharma firm is tier-I: Dr. Reddy's CEO
Vice-chairman and CEO, GV Prasad, talks about the strengths and weaknesses of the domestic pharma industry, the challenges facing DRL, its $3-billion target and the government's thoughts on FDI in pharma, in a candid conversation with ET.
Click Here for the Complete Story [PDF Format] -
Father, scientist, pharma czar
Dr. Reddy’s Labs, the first private enterprise that took pharma MNCs head on, will shortly celebrate its silver jubilee, Dr. Anji Reddy and his son Satish Reddy talk exclusively to Deccan Chronicle about the remarkable journey of the largest Indian pharma
Click Here for the Complete Story [PDF Format] -
Reddy Formula
25 years of robust, healthy way of doing business.
Click Here for the Complete Story [PDF Format]
